<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02725437</url>
  </required_header>
  <id_info>
    <org_study_id>B5091010</org_study_id>
    <nct_id>NCT02725437</nct_id>
  </id_info>
  <brief_title>Clostridium Difficile Vaccine Safety, Tolerability, and Immunogenicity Study in Japanese Adults</brief_title>
  <official_title>A Phase 1, Placebo-controlled, Randomized, Observer-blinded Study To Evaluate The Safety, Tolerability, And Immunogenicity Of Two 3-dose Regimens Of Clostridium Difficile Vaccine Administered In Healthy Japanese Adults Aged 65 To 85 Years.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The first-in-Japanese study B5091010 has been designed to evaluate the safety, tolerability,
      and immunogenicity of 2 antigen dose levels of C difficile vaccine when administered as one
      of two 3-dose regimens to healthy Japanese adults aged 65 to 85 years.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 15, 2016</start_date>
  <completion_date type="Actual">February 25, 2017</completion_date>
  <primary_completion_date type="Actual">February 25, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportions of subjects reporting local reactions (pain, erythema, and induration) and their severity, as self-reported on e-diaries</measure>
    <time_frame>Up to 14 days after each vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportions of subjects reporting systemic events (fever, vomiting, diarrhea, headache, fatigue, new or worsening muscle pain, and new or worsening joint pain) and their severity, as self-reported on e-diaries</measure>
    <time_frame>Up to 14 days after each vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportions of subjects reporting AEs (categorized according to the Medical Dictionary for Regulatory Activities [MedDRA])</measure>
    <time_frame>From the first vaccination up to 28 days after the last vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportions of subjects reporting SAEs (categorized according to the Medical Dictionary for Regulatory Activities [MedDRA])</measure>
    <time_frame>From the first vaccination until 6 months after the last vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportions of subjects with abnormal hematology and blood chemistry laboratory assessments</measure>
    <time_frame>7 days or 14 days after each vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxin A- and toxin B-specific neutralizing antibody levels, expressed as geometric mean concentrations</measure>
    <time_frame>Up to 6 months after dose 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean fold rises in toxin A- and toxin B-specific neutralizing antibody levels</measure>
    <time_frame>Up to 6 months after dose 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of subjects in each vaccine group with toxin A-specific neutralizing antibody level ≥ the specified threshold for toxin A</measure>
    <time_frame>Up to 6 months after dose 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of subjects in each vaccine group with toxin B-specific neutralizing antibody level ≥ the specified threshold for toxin B</measure>
    <time_frame>Up to 6 months after dose 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of subjects in each vaccine group with both toxin A- and toxin B-specific neutralizing antibody levels ≥ the specified threshold for toxin A and the specified threshold for toxin B, respectively</measure>
    <time_frame>Up to 6 months after dose 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of subjects in each vaccine group with fold rises in toxin A-specific neutralizing antibody levels</measure>
    <time_frame>Up to 6 months after dose 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of subjects in each vaccine group with fold rises in toxin B-specific neutralizing antibody levels</measure>
    <time_frame>Up to 6 months after dose 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of subjects in each vaccine group with fold rises in both toxin A- and toxin B-specific neutralizing antibody levels</measure>
    <time_frame>Up to 6 months after dose 3</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Clostridium Difficile Associated Disease</condition>
  <arm_group>
    <arm_group_label>Low-dose C. difficile Vaccine (accelerated schedule)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose C. difficile Vaccine (accelerated schedule)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (accelerated schedule)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-dose C. difficile Vaccine (non-accelerated schedule)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose C. difficile Vaccine (non-accelerated schedule)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (non-accelerated schedule)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Clostridium difficile Vaccine</intervention_name>
    <description>0.5 mL intramuscular injection</description>
    <arm_group_label>Low-dose C. difficile Vaccine (accelerated schedule)</arm_group_label>
    <arm_group_label>High-dose C. difficile Vaccine (accelerated schedule)</arm_group_label>
    <arm_group_label>Low-dose C. difficile Vaccine (non-accelerated schedule)</arm_group_label>
    <arm_group_label>High-dose C. difficile Vaccine (non-accelerated schedule)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.5 mL intramuscular injection</description>
    <arm_group_label>Placebo (accelerated schedule)</arm_group_label>
    <arm_group_label>Placebo (non-accelerated schedule)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male and female adults

          2. Aged 65 to 85 years

        Exclusion Criteria:

          1. Proven or suspected prior episode of Clostridium difficile associated diarrhea

          2. Unstable chronic medical condition

          3. Disease requiring significant change in therapy or hospitalization for worsening
             disease within 8 weeks before receipt of study vaccine

          4. Serious chronic medical disorders

          5. Bleeding diathesis or condition associated with prolonged bleeding time that may
             contraindicate intramuscular injection

          6. Any contraindication to vaccination or vaccine components, including previous
             anaphylactic reaction to any vaccine or vaccine-related components

          7. Subjects with congenital or acquired immunodeficiency disorders

          8. Subjects with rheumatologic disorders or other illnesses requiring chronic treatment
             with known immunosuppressant medications

          9. Active or treated leukemia or lymphoma or bone marrow disorder

         10. Residence in a nursing home or other long-term care facility, or requirement for
             semiskilled nursing care or assisted living

         11. Abnormality in screening hematology and/or blood chemistry laboratory values
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Co. LTA Sumida Hospital</name>
      <address>
        <city>Sumida-ku</city>
        <state>Tokyo</state>
        <zip>130-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Co.LTA PS Clinic</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-0025</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B5091010&amp;StudyName=A%20Phase%201%2C%20Placebo-controlled%2C%20Randomized%2C%20Observer-blinded%20Study%20To%20Evaluate%20The%20Safety%2C%20Tolerability%2C%20And%20Immunogenicity%20Of%20Two%203-dose%20Regimens%20Of%20Clostridium%20Difficile%20Vaccine%20Administered%20In%20Healthy%20Japanese%20Adults%20Aged%2065%20To%2085%20Years.</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B5091010&amp;StudyName=A+Phase+1%2C+Placebo-controlled%2C+Randomized%2C+Observer-blinded+Study+To+Evaluate+The+Safety%2C+Tolerability%2C+And+Immunogenicity+Of+Two+3-dose+Regimens+Of+Clostridium+Difficile+Vaccine+Administered+In+Healthy+Japanese+Adults+Aged+65+To+85+Years.</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2016</study_first_submitted>
  <study_first_submitted_qc>March 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2016</study_first_posted>
  <last_update_submitted>April 23, 2017</last_update_submitted>
  <last_update_submitted_qc>April 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

